David C. Dalgarno
Keine laufenden Positionen mehr
Profil
David C.
Dalgarno is the founder.
He founded Theseus Pharmaceuticals, Inc. in 2017 and served as the Chief Technical Officer from 2018 to 2022.
Dr. Dalgarno also held the position of Scientist at Schering-Plough Corp.
and Vice President-Research Technologies at ARIAD Pharmaceuticals, Inc. from 1992 to 2017.
Dr. Dalgarno obtained undergraduate and doctorate degrees from the University of Oxford.
Ehemalige bekannte Positionen von David C. Dalgarno
| Unternehmen | Position | Ende |
|---|---|---|
| ARIAD PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.06.2017 |
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Corporate Officer/Principal | - |
| THESEUS PHARMACEUTICALS, INC. | Founder | - |
Ausbildung von David C. Dalgarno
| University of Oxford | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Health Technology |
ARIAD Pharmaceuticals, Inc.
 ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology ARIAD Pharmaceuticals, Inc. operates as an oncology company, which engages in the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company was founded by Harvey J. Berger and James E. Rothman on January 8, 1992 and is headquartered in Cambridge, MA. | Health Technology |
Theseus Pharmaceuticals, Inc.
 Theseus Pharmaceuticals, Inc. BiotechnologyHealth Technology Theseus Pharmaceuticals, Inc. engages in the development of pan-variant kinase inhibitors. It focuses on the discovery, development and commercialization of transformative targeted therapies. The company was founded by William C. Shakespeare, David C. Dalgarno, Iain D. Dukes, Wei Sheng Huang and Victor M. Rivera on December 29, 2017 and is headquartered in Cambridge, MA. | Health Technology |
